Basilea Pharmaceutica is a Switzerland-based biopharmaceutical company, established in 2000 as a spin-out from Roche with the divestment of its anti-infective portfolio. Basilea was listed on the SIX Swiss Stock Exchange in 2004 and is well funded through its key near-term milestones. Revenue growth will be driven from its two marketed anti-infectives, Cresemba (antifungal, for invasive mould infections) and Zevtera (antibiotic, for hospital infections), which are commercialised globally through partners such as Pfizer and Astellas. Basilea has several oncology assets in clinical development, which represent the next pillar of growth, including derazantinib, a pan-FGFR kinase inhibitor that is in a registrational Phase II study for bile duct cancer. Derazantinib is also being tested in urothelial cancer, with plans to initiate clinical development in gastric cancer in H220. Lisavanbulin, a potential novel checkpoint inhibitor, is forecast to enter Phase II development for glioblastoma in H220.
In this video, CEO David Veitch discusses the impact of COVID-19 on Basilea’s key revenue drivers and clinical trials, as well as recent updates from its pipeline.